Reconnecting

The current page stays visible while onset.to reconnects in the background.

Compass Files Psilocybin Application with FDA as U.S. Government Supports Ibogaine Development and the Field Assesses Midterms

Open original

Compass Pathways has submitted a psilocybin new drug application to the FDA, while the U.S. government has tapped Mark Cuban's company to support ibogaine development for PTSD. The government has also committed to funding a $20 million real-world evidence network. Josh Hardman reviews these developments alongside the potential implications of the U.S. midterms for psychedelics and Delix Therapeutics' $100 million Series C raise. The episode surveys news from the preceding two weeks but supplies few details about the individual developments.